Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian’s financial ...

Cartesian Growth Corporation III (Nasdaq: CGCT), a special purpose acquisition company (“CGCT”), today announced that its ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...

Factorial Inc. on Thursday announced partnerships with drone integrators KULR Technology Group Inc. KULR, Tulip Tech, and ...

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in ...

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...

View Cartesian Growth Corp. III Class A CGCT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...

Cartesian Growth Corporation III (Nasdaq: CGCT), a special purpose acquisition company (“CGCT”), today announced that its previously announced business combination (the “Business Combination”) ...

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian's financial flexi ...